Tislelizumab for lung cancer with brain metastases
Part of Cancer clinical trials.
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV lung adenocarcinoma that cannot be removed with surgery or radiation
- You have brain metastases that are not causing symptoms
- You have not received any treatment for advanced lung cancer before
- Your overall health status is good (ECOG score 0 or 1)
- You have at least one measurable tumor outside the skull
- Your life expectancy is more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
This trial tests a new combination for advanced lung cancer: an immunotherapy drug (tislelizumab) plus standard chemotherapy, and adds a common allergy medicine (diphenhydramine) to see if it improves outcomes. It's for people who haven't had prior systemic treatment for their lung cancer and are generally healthy.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.